Last reviewed · How we verify
NCT03642080
MRI Predictors of Response to Tumor Treating Fields
trial in Glioblastoma Multiforme in 48 participants. Status unknown.
30 September 2021
Quick facts
| Lead sponsor | New York Presbyterian Brooklyn Methodist Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 1 December 2018 |
| Primary completion | 30 September 2021 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across United States |
Conditions studied
- Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
Sponsor
New York Presbyterian Brooklyn Methodist Hospital
Who can join
18 and older, any sex, with Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with glioblastoma, an aggressive brain tumor, are recommended to undergo treatment with tumor treating fields using the Optune device as part of standard of care therapy. While undergoing treatment, patients are monitored regularly with brain MRI scans to look for tumor progression, but there are currently no means to predict which, or when, patients will progress. The purpose of the current study is to prospectively analyze these MRI scans to look for subtle imaging markers that can predict for future brain tumor progression while undergoing tumor treating field therapy.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumor-Treating Fields in Glioblastomas: Past, Present, and Future.
Guo X, Yang X, Wu J, Yang H, et al · · 2022 · cited 39× · PMID 35954334 · DOI 10.3390/cancers14153669 -
Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.
Szasz AM, Arrojo Alvarez EE, Fiorentini G, Herold M, et al · · 2023 · cited 9× · PMID 36765840 · DOI 10.3390/cancers15030880 -
Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma.
Iv M, Naya L, Sanan S, Van Buskirk SL, et al · · 2024 · cited 6× · PMID 37931176 · DOI 10.1177/19714009231207083
Verify or expand the search:
- PubMed search for NCT03642080
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioblastoma Multiforme
Currently open trials in the same condition.
- NCT06466031 — Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] · NA · recruiting
- NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
- NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
- NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
- NCT06329570 — Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multif · Phase 1, PHASE2 · recruiting
Other New York Presbyterian Brooklyn Methodist Hospital trials
Trials by the same sponsor.
- NCT06486116 — Effectiveness of Task Specific Home Exercise Program · NA · recruiting
- NCT05092490 — Serratus Anterior Plane Block Combined With Transversus Thoracic Muscle Plane Block Versus Conventional Local Anesthetic · NA · completed
- NCT03828929 — Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock · Phase 3 · terminated
- NCT04691687 — OUTpatient Intravenous LASix Trial in Reducing Hospitalization for Acute Decompensated Heart Failure · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03642080 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York Presbyterian Brooklyn Methodist Hospital
- Last refreshed: 19 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03642080.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing